Q2 EPS Estimates for Daré Bioscience Increased by Analyst

Daré Bioscience, Inc. (NASDAQ:DARE) – Stock analysts at Brookline Capital Management lifted their Q2 2025 earnings per share (EPS) estimates for shares of Daré Bioscience in a research note issued to investors on Tuesday, May 13th. Brookline Capital Management analyst K. Dolliver now expects that the biotechnology company will post earnings per share of ($0.48) for the quarter, up from their prior estimate of ($0.62). The consensus estimate for Daré Bioscience’s current full-year earnings is ($0.49) per share. Brookline Capital Management also issued estimates for Daré Bioscience’s Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.57) EPS and FY2025 earnings at ($2.03) EPS.

Daré Bioscience (NASDAQ:DARE) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.13. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.60 million. During the same period in the previous year, the business posted ($0.84) earnings per share.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Daré Bioscience in a report on Tuesday, April 1st.

Daré Bioscience Price Performance

Daré Bioscience stock opened at $2.88 on Friday. The firm has a market capitalization of $25.49 million, a price-to-earnings ratio of -4.88 and a beta of 1.20. The company’s 50 day simple moving average is $2.92 and its 200 day simple moving average is $3.18. Daré Bioscience has a fifty-two week low of $2.67 and a fifty-two week high of $7.56.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. AMH Equity Ltd boosted its holdings in Daré Bioscience by 50.0% during the fourth quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 50,000 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Daré Bioscience during the 4th quarter worth about $52,000. Renaissance Technologies LLC grew its holdings in shares of Daré Bioscience by 6.7% in the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 4,300 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Daré Bioscience by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after acquiring an additional 3,593 shares in the last quarter. 6.70% of the stock is owned by institutional investors and hedge funds.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.